Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Tel Aviv, Israel
Countries of investment
  • Israel
  • United States
  • Canada
  • Switzerland
  • Germany
Investment stages
  • Seed
  • Series A
  • Series B
  • Growth
Industries
  • Asset Management
  • Public Equities
  • Hedge Funds
About
Arkin Bio fuels life sciences breakthroughs as part of Arkin Capital’s multi-stage platform, targeting early- and mid-stage biotech innovation in immunotherapy, novel therapeutics, diagnostics, and digital health, leveraging deep pharmaceutical heritage to scale companies toward global impact.
Min check size
$500K
Max check size
$5M
Fund size
NPS

Investment Thesis

Arkin Bio fuels biotech and health tech innovation through early-stage venture capital, supporting novel therapeutics, diagnostics, and digital health solutions that accelerate medical progress.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Run by long-tenured public market investors with deep expertise in fundamental equity research, portfolio management, and risk-adjusted capital allocation.

Team

Mori Arkin - Founder and Chairman

Nir Arkin - Chief Executive Officer

Portfolio

Keros Therapeutics

HI-Bio

Eleos

Laguna

ARTSaVIT

Metabomed

Oncorus

Pi Therapeutics

Werewolf Therapeutics

BioSight

Bluejay Therapeutics

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp